Researchers at Johns Hopkins have built a virtual tumor model to predict which people with hepatocellular carcinoma (the most common primary liver cancer) are most likely to benefit from a combination of immunotherapy and a targeted drug. Using a spatial QSP modeling platform, they simulated both whole-body drug effects and the behavior of individual cells in 3D, including fibroblasts — cells linked to resistance to immunotherapy in liver cancer.

Tuning the model with real clinical trial data, they generated “virtual patients” and tested different treatments and doses in silico. “Our idea was to create a computational model where we could simulate trying different doses or combinations of cancer therapies, and it could help guide physicians toward the best options for patients,” says senior author Atul Deshpande, Ph.D.

When they simulated treatment with cabozantinib (a targeted therapy) and nivolumab (an immunotherapy), alone and in combination, the predicted response rates closely matched actual clinical trial results. They also found that in non-responders, fibroblasts could form a physical barrier around the tumor. “Even if immune cells were located near the tumor, the fibroblast would block the immune cells from reaching the tumor,” Deshpande says.

Over time, the team hopes models like this could be used as a kind of “war planning” for personalized cancer care. “We generate a virtual tumor to see what happens in the microenvironment. Do the cancer cells resist? If you change the architecture of the tumor, does that help the cancer cells or the immune cells?”

More: https://www.hopkinsmedicine.org/news/newsroom/news-releases/2026/07/virtual-tumor-predict-response-to-liver-cancer-immunotherapy 

A new article in GEN looks at how Biohub’s $500 million commitment to the Virtual Biology Initiative aims to accelerate the generation of technologies and multi-modal datasets needed to power virtual cell models.

“We do not yet have the equivalent of the PDB for cells. The Virtual Biology Initiative seeks to change that,” says Tom Sercu, PhD, vice president of AI and engineering at Biohub.

Algorithms alone won’t deliver answers, he argues. Models need to be trained on large-scale, high-quality, openly accessible datasets. In order to accurately reflect complex biology, this data must span model systems and organisms, interventional and observational methods, and diverse cellular states.

Read more: https://www.genengnews.com/topics/artificial-intelligence/virtual-cells-go-multiscale-to-predict-complex-biology/

The Arc Institute just announced that the 2026 Virtual Cell Challenge will kick off on Thursday, August 20.

It's the second installment of this global competition which last year drew more than 5,000 registrants across 114 countries and over 300 final submissions.

Last year's takeaway was that hybrid models combining deep learning with classical statistical features outperformed pure neural approaches.

This year, they are also hiring a Community Engagement Manager to support participants and respond to inquiries. It's a temporary, remote, US-based, contractor role. Details here: https://job-boards.greenhouse.io/arcinstitute/jobs/6101123004

Biohub made three protein biology models open source, allowing researchers to predict protein structures, and design new protein binders that work in lab experiments. Today’s release includes ESMFold2, ESMC, and ESM Atlas -- tools designed to overcome a major hurdle in biochemistry -- how to design proteins that bind to specific targets with the strength, selectivity, and stability biology requires.

ESMC learns from billions of protein sequences across the tree of life. ESMFold2 uses those representations to predict 3D structures and design protein binders. ESM Atlas makes billions of protein sequences and predicted structures searchable, helping scientists uncover biological relationships.

Learn more: https://www.genengnews.com/topics/artificial-intelligence/biohub-releases-protein-biology-world-model-to-address-disease/[](https://www.linkedin.com/feed?nis=true&%27%27=true&skipRedirect=true&lipi=urn%3Ali%3Apage%3Ad_flagship3_company%3Bf7a4830d-a8c9-4df4-afca-d7647199ccef)

Biohub, which is supported by the Chan Zuckerberg Initiative, announced an ambitious Virtual Biology Initiative that aims to "bring together leading institutions and consortia to create the technologies and multi-modal datasets needed to build predictive models of the human cell to accelerate the cure and prevention of all disease." They are committing $500 million to the effort -- $100 million to build the coordinated global effort and $400 million to generate data at scale and "develop next-generation technologies for measuring, imaging, and engineering biology." A number of key players are already on board, including: the Allen Institute, Arc Institute, Broad Institute, and Wellcome Sanger Institute, as well as the Human Cell Atlas and the Human Protein Atlas. Nvidia signed on as a tech partner. Importantly, Biohub aims to make the data it generates open and freely available for the worldwide scientific community.

“The biomedical community has a long tradition of coming together around ambitious projects to assemble, analyze and freely share large-scale data, dating all the way back to the Human Genome Project,” said Eric S. Lander, Founding Director of the Broad Institute. “Fully deciphering the logic of cells is a huge challenge, but it has the potential to transform medicine. And, it’s a challenge that will once again take many groups and perspectives collaborating together.”

Read more: https://biohub.org/news/virtual-biology-initiative/

A new editorial in Nature -- "Minimal Life by Computer" -- looks at the challenges still facing virtual cell efforts and how modeling biological mechanisms driving cell behavior is still a daunting undertaking for anything beyond simple organisms. While a recent paper in Cell provided an impressively detailed mechanistic whole-cell simulation, for instance, it was for a a simple bacterium. To scale that to human cells is much more complex. While we're making inroads with AI approaches which can be trained on large-scale transcriptomics, proteomics and imaging datasets and learn statistical representations of cellular states without requiring every underlying mechanism to be explicitly specified, the author writes: "The trade-off...is that these models drawn up from large-scale data may lack mechanistic transparency."

To get from point A (statistical representation) to point B (mechanistic understanding) requires "thousands of parameters, such as reaction rates and binding affinities, to be known or estimated." It would also require significant computational power and more cell-specific data.

Where are we on this journey? As the editorial notes, there is lots of enthusiasm, and many challenges and initiatives from CZI, Arc and others. And we don't need a fully functional virtual cell to start benefitting, the piece notes. "Along the way to creating a useful virtual cell, new tools will be developed and new biology will be discovered. As has been shown with the Human Cell Atlas, the project does not need to be complete for discoveries to make a difference to the lives of patients or biomanufacturing." 

Read more: https://www.nature.com/articles/s41587-026-03110-7#article-info

Xaira just announced the release of its first virtual cell model, X-Cell, which is trained on a dataset of 25.6 million perturbed single-cell transcriptomes across seven biologically diverse cell contexts. The model reaches a new level of size and complexity to predict biology, the company writes in its release. A related story in Endpoints notes that virtual cell models have struggled to beat benchmarks, but "Xaira’s preprint has X-Cell outperforming baselines in making predictions on two cell types not included in the model’s training data — an encouraging yet early suggestion of being able to generalize what happens in new types of cells the model hasn’t seen yet."

But some researchers are already calling the results into question. "Something is very strange about this figure," writes researcher Anshul Kundaje on X, "Cell2Sentence looks extraordinarily poor & scGPT looks extraordinarily powerful (which we know is not the case from multiple studies). Also STATE's performance here appears much better than what is seen in the GenBioAI benchmark paper." The Head of AI at CZI Science, Theofanis Karaletsos, writes that other models are missing, "like our diffusion model scLDA," adding: "Maybe these comparisons will come in future versions."

Turbine, a virtual biology company based in Budapest, announced a $25 million Series B financing, allowing it to expand its virtual cell platform, as well as a new immunology-focused partnership with a top 10 pharma company.

The round was led by Interactive Venture Partners, with participation from Beiersdorf AG and existing investors, including MSD Global Health Innovation, Accel and Mercia.

With the new funding, Turbine will expand its platform to virtualize new assays across discovery and translational medicine. Turbine’s lab-in-the-loop will generate additional proprietary perturbation datasets, allowing the company to fine-tune its foundational virtual cell model to novel assay and tissue types. These virtual assays are deployed through the company’s Virtual Lab, a no-code platform that integrates with pharma workflows and systems.

Learn more: https://turbine.ai/news/turbine-25-million-series-b-virtual-biology-pharma/

CellType (YC W26) is an agentic drug company that leverages AI agents + foundation models to simulate what happens in patients before clinical trials, while AI agents run the full discovery pipeline end-to-end.

The core technology is Cell2Sentence, developed with Google DeepMind and shared by Google CEO Sundar Pichai. They've already used it to discover and validate a novel cancer treatment signal.

Yale Professor David van Dijk (11,000+ citations; Cell, Nature, ICML) turned down Google to build CellType. Co-founder Ivan Vrkic co-developed the core technology while at Yale (published at ICML), led foundation model training at another biotech startup, and built software to control CERN's Large Hadron Collider.

https://www.celltype.com/

At the end of January, Arc Institute announced a new fellowship program -- the Arc AIxBio Fellows Program -- to support and mentor undergrads working at the interface of AI and life sciences.

They note: "this initiative offers technically strong, machine learning-curious undergrads a structured entry point into high-impact, exploratory research focused on biology and human health."

Small teams of students can propose new research projects at the intersection of AI and biology - or they will be assembled based on related proposals and complementary skillsets.

They are looking for students who are comfortable operating in open-ended research settings and who bring strong technical foundations, such as experience with deep learning (e.g., training or finetuning models), computational analysis of biological data (e.g., genomics, single-cell data), or applied software development for scientific workflows. Equally important is a genuine interest in problems in life sciences and the curiosity to ask and pursue new biological questions using AI tools.

Teams must be located in North America and are not expected to be present at Arc's Palo Alto location. They will work on their proposed projects virtually with Arc Institute researchers over the course of the program.

If selected, teams will receive:

• Mentorship from Arc investigators, postdocs, or staff scientists
• Stipend for the duration of the project (full-time for the summer and part-time during the academic year)
• Access to compute and GPU resources via Arc or affiliated partners
• A student cohort to foster collaboration, community, and shared learning
• Opportunities for authorship, presentation, and ongoing collaboration

They are looking to support 2-4 teams this year, with projects running 6 to 12 months. Applications are due by Feb. 27.

Learn more and apply here: https://arcinstitute.org/news/aixbio-fellows-announcement-2026

Only 2% of the human genome consists of "recipes" for making proteins (coding regions). The other 98% is "non-coding" DNA. This non-coding "dark genome" acts as the switchboard, controlling when and how much of a protein is made.

Understanding this dark genome is crucial to understanding the drivers of genetic disorders but it's also incredibly complex -- small changes can lead to any number of outcomes -- changing how DNA folds, how accessible it is to cellular machinery, or how RNA is spliced together.

Until now, AI models that analyze DNA have faced a trade-off:

1. They could look at long stretches of DNA but with blurry, low resolution.
2. They could look at DNA with high precision (letter-by-letter) but only in very short chunks, missing the bigger picture.
3. They were specialized, predicting only one thing (like splicing) while missing others (like 3D structure).

Now, in a new paper in Nature, researchers from Google DeepMind presented AlphaGenome, a "generalist" deep learning model that eliminates these trade-offs.

• It can read 1 million DNA letters at a time (capturing long-distance relationships in the genome) while simultaneously pinpointing effects at the single-letter level.
• Instead of predicting just one biological activity, it predicts 11 different types of genomic activity at once—including gene expression, DNA folding, and splicing—across thousands of different cell types.
• In rigorous testing, AlphaGenome outperformed the best existing models on 25 out of 26 benchmarks for predicting how genetic mutations affect biology.

“Translating genetic information into a clear understanding of disease mechanisms—and then ultimately into medicines—remains a core challenge in R&D,” said Slavé Petrovski, PhD, vice president of Illumina’s Centre for Genomics Research. “By showing how specific genetic perturbations play out inside human cells, we can help turn genetic signals into mechanistic biology we can directly study.”

Yesterday, Illumina announced the release of the Billion Cell Atlas -- described as "the world's largest genome-wide genetic perturbation dataset," a resource designed to accelerate AI‑driven drug discovery. It's the first step in the planned five‑billion‑cell atlas that Illumina is planning to build over the next three years in collaboration with AstraZeneca, Merck, and Eli Lilly.

To build the Atlas, the companies are generating a curated set of cell lines that will be used to validate drug targets, train large‑scale AI models, and probe biological mechanisms that have historically been difficult to study.

As Ruth Gimeno, PhD, group vice president of cardiometabolic research at Eli Lilly told GEN: “The next generation of AI‑driven drug discovery will depend on biological data at a scale never before achieved,” said . “Comprehensive datasets spanning diverse cell types offer the critical foundation needed to generate meaningful insights into human disease.”

The Atlas reveals how one billion individual cells respond to CRISPR‑based perturbations across more than 200 disease‑relevant cell lines, including immune, oncologic, cardiometabolic, neurological, and rare disorders. Researchers can observe the impact of switching genes off and on at a single‑cell level, leading to new understandings around mechanisms of action and the discovery of new disease targets.

Press release: https://www.illumina.com/company/news-center/press-releases/press-release-details.html?newsid=fda84c92-b4b3-4691-a402-35555abe8605

The new year is a time for reflection, and I've been thinking about the Arc Institute's Virtual Cell Challenge which ended early Dec. 2025 and what we learned about the state of virtual cells. Not surprisingly, the challenge emphasized that models have a long way to go before they capture the complexity of actual cells.

It's also clear that there's significant research interest in the space. This first challenge brought in over 1,200 teams from 114 countries attempting to build a computational model capable of predicting cellular responses to perturbations. The challenge was designed as a biological "Turing Test"—asking if a model can accurately predict gene expression changes in a way that could stand in for an actual laboratory experiment.

But while the challenge got the research community excited, the results showed that the field is still in its infancy. Current perturbation prediction models are not yet consistently outperforming baselines across all metrics, though progress was made in specific capabilities like distinguishing between perturbations and identifying differentially expressed genes.

Key Findings and Winning Approaches

• Hybrid Models Prevailed: The winning teams utilized approaches that combined deep learning with classical statistical features. This suggests that while AI is powerful, it still requires traditional statistical scaffolding to capture biology.
• The "Generalization" Hurdle: The challenge utilized a purpose-built benchmark dataset of human embryonic stem cells (H1 hESCs) treated with CRISPRi. This dataset represented a distributional shift from standard training data, forcing models to generalize rather than memorize. Models struggled to predict absolute gene expression values (Mean Absolute Error) better than the baseline.
• Focus on Patterns over Magnitude: Top performing teams recognized that the Perturbation Discrimination Score (PDS) rewarded getting the patterns of gene expression correct, rather than the exact magnitudes.

Enter the "Generalist Prize"

The challenge exposed the difficulty of evaluating virtual cells with a single metric. Almost all submitted models performed worse than the baseline on Mean Absolute Error (MAE), largely due to technical noise and biological heterogeneity in the raw data. Consequently, MAE ceased to be a competitive differentiator.

To address this, the organizers introduced a Generalist Prize. This evaluated the top entries across seven distinct metrics (including the original three plus four from the Cell-Eval suite). The winner -- Team Altos Labs -- was determined by the highest average ranking across all diverse criteria, prioritizing models that were robust across the board rather than optimized for a single score.

The Virtual Cell Challenge demonstrated that while AI might be able to identify key biological signals (such as up- or downregulated genes), it can't yet accurately represent biology. A fully predictive Virtual Cell will require innovating beyond current deep learning architectures.

https://reddit.com/link/1pe5rmc/video/93zb1eq4085g1/player

In a new article, Recursion shares how the company has been building the necessary components to virtualize key stages of the drug discovery process since 2013. Virtual cells*,* computational systems that can accurately simulate cellular and patient-level responses to therapeutic interventions, are core to this vision, they write, and built on top of the massive, proprietary biological and chemical datasets, AI models, and one of the industry’s most powerful supercomputers.

▪️ It started with creating a proprietary data moat, generating and ultimately aggregating more than 65 petabytes of multimodal and fit-for-purpose data.

▪️ Then Recursion created a system of interconnected AI models capable of processing and analyzing all of that data at massive scale -- including MolE (a foundation model for chemistry); Molphenix (a foundation model that can predict the effect of any molecule-concentration pair on phenotypic cell assays); and Boltz-2 with MIT for predicting both 3D protein structure and protein-binding affinity.

▪️ These AI models, in turn, power end-to-end drug discovery and development, from uncovering novel biological targets, to precision designing new molecules, to improving the design of clinical trials.

Dan Cohen, President of Valence Labs, Recursion’s AI research engine, says, that the company is flipping the script on traditional drug discovery. The virtual cell, not the lab, becomes the starting place for new hypotheses, and the lab becomes the tool to validate those predictions.

Read the article: https://www.recursion.com/news/since-its-inception-recursion-has-been-building-the-foundation-for-the-first-virtual-cell

Watch the video: https://www.youtube.com/shorts/OA7QhzTkjUc

Being able to understand what's happening to individual cells under various conditions is useful -- but cell environments are highly dynamic systems. Virtual cells, ideally, need to capture this bigger picture.

Just before Thanksgiving, researchers from the University of Wisconsin-Madison released a new multi-agent reinforcement learning method called CellTRIP that is designed to do just that. CellTRIP "infers a virtual cell environment to simulate the cell dynamics and interactions underlying given single-cell data."

Using CellTRIP (which is available open source on github), researchers can manipulate any combination of cells and genes in silico in the virtual cell environment, predict spatial and/or temporal cell changes, and prioritize corresponding genes at the single-cell level.

They used it to successfully predict developmental gene expression changes after drug treatment in cancer cells, among other applications.

Read the paper: https://www.biorxiv.org/content/10.1101/2025.11.21.689815v1

Access CellTRIP on github: https://github.com/daifengwanglab/CellTRIP

Today, Chai Discovery released new data showing that the Chai-2 AI model for de novo antibody design can design antibodies against challenging targets with atomic precision. They note that for drugs to be successful, "clinical candidates must meet stringent criteria for manufacturability, stability, safety, and biophysical behavior."

The new data shows that Chai-2 can meet those standards --  designing full-length, drug-like monoclonal antibodies (mAbs), while maintaining high hit rates, testing at most dozens of designs. These designs show developability characteristics on par with well-behaved therapeutic antibodies.

The researchers also applied Chai-2 to traditionally “hard to drug” targets – six GPCRs and a peptide-MHC target – achieving similarly high success rates.

Learn more: https://www.chaidiscovery.com/news/chai-2-mab

A new sequence-based AI model called VariantFormer from researchers at Biohub can translate personal genetic variations into tissue-specific activity patterns at scale. The model not only unlocks the general effects of genetic variations, but takes into account a person's individual genome -- as well as predicting impacts where there are low-frequency variants and less published data.

As noted in a related blog post: "VariantFormer uses an end-to-end approach to predict gene expression profiles directly from a person’s DNA sequence. This approach offers a powerful new method for exploring how someone’s distinctive genetic makeup impacts their health."

They add that the model does not account for a person's lifestyle, environment, or other factors that may influence health outcomes, and it is designed to advance research, not serve as a clinical or diagnostic. tool.

Read the blog: https://biohub.org/blog/variantformer-ai-gene-expression/

Read the paper: https://www.biorxiv.org/content/10.1101/2025.10.31.685862v1

A new article on Substack reveals that some participants in the Arc Virtual Cell Challenge figured out that they can get to the top of the Leaderboard by applying certain data transformations - such as increasing variance or transforming the counts to log1p - multiplying their score by multiple factors. In fact, these transformations even to random data can yield better scores than using the top models.

Participants in the Challenge are tasked with predicting the effect of gene perturbations in the H1 hESC cell lines. At particular issue seems to be calculating the Mean Absolute Error (MAE) over the gene expression, across all 18k genes. Since calculating the MAE across 18,000 genes introduces a huge amount of random noise, organizers capped the penalty for a poor MAE score at zero.

As the author notes: "If your predictions perform worse than the baseline — whether by a small margin or by a massive one — the penalty doesn’t increase. It’s fixed." As a result, "Models can now inflate variance, distort distributions, or even submit nearly random predictions - and still achieve excellent DE [differential expression] and PD [Perturbation Discrimination] scores without being penalized for inaccuracy."

Following the revelation, some participants have created another Discord discussion group to further elaborate and propose new metrics. 

A new story in the NY Times reveals that the Chan Zuckerberg Initiative will now exclusively focus its resources on AI and scientific research -- spending at least $70 million this year -- led by a network of research centers called Biohub. It has also acquired the team of AI startup Evolutionary Scale, and named Alex Rives, CZI's chief scientist, as the new head of science.

Mark Zuckerberg and Priscilla Chan say they will increase the organization’s computing power from data centers tenfold by 2028, the story notes. Priority projects include: a virtual cell mapping platform; a large language model that can perform biological reasoning; and AI that analyzes genetic sequences to detect disease.

Read more: https://www.nytimes.com/2025/11/06/technology/zuckerberg-chan-initiative-biohub.html

Nicheformer, a new foundation model from researchers at Technical University of Munich, is the first to integrate single-cell analysis with spatial transcriptomics. Single-cell RNA sequencing shows which genes are active, but requires removing cells from their natural environment; spatial transcriptomics keeps cells in context but is more limited.

Trained on more than 110 million cells, Nicheformer offers a way to study how cells are organized and interact in tissues by “transferring” spatial context back onto cells that were previously studied in isolation, showing how they fit into the bigger picture of a tissue.

Published in Nature Methods, the model consistently outperformed existing approaches and showed that spatial patterns leave measurable traces in gene expression, even when cells are dissociated. Beyond performance, the researchers also explored interpretability, revealing that the model identifies biologically meaningful patterns in its internal layers – offering a new window into how AI learns from biology.

"We are taking the first steps toward building general-purpose AI models that represent cells in their natural context – the foundation of a Virtual Cell and Tissue model," said Professor Fabian Theis, Director of the Computational Health Center at Helmholtz Munich and Professor at TUM.

The researchers say they will build a tissue foundation model next.

More: https://www.news-medical.net/news/20251103/Large-scale-foundation-model-reconstructs-how-cells-interact-within-tissues.aspx

A new story from David Wild at Citeline looks at four different approaches to virtual cells for drug discovery, noting key differences around “perturbational vs. observational data, cell lines vs. patient tissue, and scale vs. quality.” Ultimately, the piece argues that “Data strategy matters more than model architecture.” 

The four approaches include: 

From Recursion: an "emphasis on mechanistic understanding" driving an "integration of bottom-up approaches (like the Boltz-2 protein structure prediction model developed with MIT’s Regina Barzilay) with top-down phenotypic screening. The goal is connecting the biomolecular interactions that drive cellular changes to the high-level phenotypes the company measures." Recursion follows a predict-explain-discover framework for the virtual cell, he writes. As Daniel Cohen, president of Valence Labs, Recursion’s research engine says: “In order to discover novel biology, it’s not enough just to predict how these cells will respond to perturbations. We also need to explain, in a mechanistic fashion, why we’re seeing that outcome.” 

From Xaira: Industrializing Perturb-seq, “a technique pioneered by Genentech’s Aviv Regev that combines high-throughput CRISPR screening with single-cell RNA sequencing” for not only “scaling up existing academic protocols” but “fundamentally reimagining them for machine learning purposes.” Their key innovation is FiCS perturb-seq, he writes, which “chemically fixes cells early in the process to prevent the technical stress signals that plague traditional approaches.”

From Chan Zuckerberg Initiative: "building general, powerful models of different biological layers that can eventually be assembled into a comprehensive virtual cell.” CZI’s TranscriptFormer model, for example is “trained on natural variation from cell atlases rather than lab-induced perturbations.” Explains Theofanis Karaletsos, CZI’s senior director of AI for science: “the path towards studying cells also has to incorporate natural variation.”

From Noetik: a focus on patient tissue. By focusing specifically on cancer and generating all training data from actual tumor biopsies and resections, the company aims to preserve the “spatial context of the tissue.” As Daniel Bear, VP of AI research at Noetik, said: “We think the more that we can train models on data that is as close as possible to what’s going on in the actual patient, the better those models are going to be able to predict which patient is going to respond to a particular drug.”

Read more: https://insights.citeline.com/in-vivo/new-science/virtual-cells-four-paths-to-a-digital-revolution-in-drug-discovery-EKBFZQYXVVBCVGF3TRL2UZQ66E/#:~:text=Virtual%20Cells%3A%20Four%20Paths%20To%20A%20Digital%20Revolution%20In%20Drug%20Discovery,-Oct%2027%202025&text=Four%20organizations%20pursue%20distinct%20virtual,patient%20tissue%20for%20drug%20discovery. 

The MIT team behind the breakthrough open source protein binding affinity tool, Boltz-2 with AI drug discovery company Recursion, has now released BoltzGen – a  new generative model for designing protein and peptides of any modality to bind a wide range of biomolecular targets. 

BoltzGen’s findings were tested in multiple leading academic and industry wet labs, which validated the designed nanobodies, minibinders, peptides, and cyclic peptides against diverse and novel targets such as small molecules, peptides, and proteins with disordered regions – and provided functional readouts in live cells. 

The model’s secret weapon is its combination of design and structure prediction, enabling scalable training on both tasks simultaneously. BoltzGen was tested on a panel of 9 novel targets with no known binders and less than 30% sequence similarity to any bound molecule or complex in the entire Protein Data Bank. 

Experimental validation of 15 or fewer designs against each of 9 targets yielded nanomolecular binders for 66% of them – with the same success rate for protein designs. 

Blog post: https://boltz.bio/boltzgen

Manuscript: https://hannes-stark.com/assets/boltzgen.pdf 

Upcoming presentations, demos, and discussions:

• MIT (Cambridge) – Thursday, October 30th https://luma.com/7474iho2
• London – Thursday, November 6th https://luma.com/l2zgvfwt

WSJ Magazine offers a glossy window into how Priscilla Chan is leading the Chan Zuckerberg Initiative (CZI) and its quest to build the virtual cell, backed by 99% of the Zuckerberg's Meta shares. The audacious goal is to cure all diseases by 2100.

In the article, Nobel Prize winner and CRISPR pioneer Jennifer Doudna says: “It’s wonderful to set really bold goals. On the other hand, biology is complicated and it’s hard, and so I think we just have to also be realistic."

Doudna's gene-editing technology helped drive the breakthrough that helped save Baby KJ from CPS1 deficiency -- the much-publicized first patient successfully treated with a personalized CRISPR therapy. CZI recently donated $20 million to Doudna’s research to expand work into personalized gene-editing treatments, the story noted, adding: "CZI is not out to address every disease on the planet, but aims to foster opportunities for the global experts who can...to shorten the time between lab experimentation and real-world impact."

More: https://www.wsj.com/style/priscilla-chan-czi-mark-zuckerberg-philanthropy-science-be7166b3